Role of the Immune System in Preventing Laryngeal Cancer

European Institute of Oncology3 enrolled

Overview

Laryngeal dysplasia and progression to carcinoma: investigating genetic and immune alterations predictive of malignant transformation

Evaluate the immune population of TILs in LDy lesions with a high or low risk of malignant transformation. Analyze gene expression profiles in LDy lesions categorized by their risk of malignant progression.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Head & Neck Cancer

Eligibility

Sex: ALLMin age: 18 YearsMax age: 99 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Histopathological diagnosis of laryngeal dysplasia. * Age \>18 years and informed consent. Exclusion Criteria: * Prior surgical, radiotherapeutic, or oncologic treatments for head and neck regions. * Congenital or acquired immunodeficiency disorders. * Synchronous malignancies. * Immunosuppressive therapy. * Age \<18 years or absence of research consent.

Locations (1)

European Institute of Oncology

Milan, MI, Italy

RECRUITING

Outcomes

Primary Outcomes

differences in TILs counts

detection of differences in TILs counts from Laryngeal dysplasia to progression to carcinoma

Time frame: 2 years

Secondary Outcomes

Differences in TILs counts in LDy lesions

Detection of Differences in TILs counts in LDy lesions categorized by their risk of malignant progression

Time frame: 2 years

Central Contacts

Marta Tagliabue, MD

CONTACT

00390257489405 marta.tagliabue@ieo.it

francesca lombardi

CONTACT

00390257489425 francesca.lombardi@ieo.it

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.